Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kelong capsule is a Traditional Chinese Medicine (TCM) formula developed by Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is primarily indicated for the treatment of nonalcoholic fatty liver disease (NAFLD). The formulation is based on TCM principles aimed at clearing heat, resolving phlegm, and activating blood circulation, which are therapeutic strategies used to address the underlying patterns of metabolic dysfunction and hepatic steatosis. Clinical evaluation of the Kelong capsule has involved randomized, double-blind, controlled trials (such as ChiCTR2200061319) focusing on its efficacy in reducing hepatic fat content, as measured by the Controlled Attenuation Parameter (CAP), and improving liver function markers like alanine aminotransferase (ALT). It is typically administered as an oral capsule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kelong capsule.